Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 46,000 H-shares on 13 April 2026 through on-market transactions.

The buyback was executed within a price range of HKD 28.68–30.70 per share, resulting in an aggregate consideration of HKD 1.37 million. The repurchased shares have been retained as treasury stock.

Following the transaction, issued share capital remains at 136.22 million shares, while treasury shares increased to 155,800, representing 0.11 % of the share capital authorised for repurchase under the mandate approved on 12 February 2026. Cumulative buybacks under this mandate now total 155,800 shares, equivalent to 0.11 % of the shares outstanding on the mandate date.

Under Hong Kong Listing Rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 13 May 2026.